

HBRN Adult Cohort Manuscript: Low Incidence of Adverse Outcomes in Adults with Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy

The CONTENTS Procedure

Data Set Name	A_AC.BASELINECHAR	Observations	1771
Member Type	DATA	Variables	85
Engine	V9	Indexes	0
Created	08/04/2022 17:15:56	Observation Length	736
Last Modified	08/04/2022 17:15:56	Deleted Observations	0
Protection		Compressed	NO
Data Set Type		Sorted	NO
Label			
Data Representation	WINDOWS_32		
Encoding	wlatin1 Western (Windows)		

Engine/Host Dependent Information	
Data Set Page Size	65536
Number of Data Set Pages	21
First Data Page	1
Max Obs per Page	88
Obs in First Data Page	72
Number of Data Set Repairs	0
ExtendObsCounter	YES
Filename	L:\HepB\NIDDK Repository Data Archive\Adult Cohort\SAS Datasets\Analytic Datasets\baselinechar.sas7bdat
Release Created	9.0401M7
Host Created	W32_10PRO
Owner Name	PITT\STEPH19
File Size	1MB
File Size (bytes)	1441792

Alphabetic List of Variables and Attributes						
#	Variable	Type	Len	Format	Informat	Label
40	ALB	Num	8	32.10	32.10	Albumin (g/dL)
33	ALT	Num	8	32.10	32.10	Labs: ALT (IU/L)
36	AST	Num	8	32.10	32.10	Labs: AST (IU/L)

HBRN Adult Cohort Manuscript: Low Incidence of Adverse Outcomes in Adults with Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy

The CONTENTS Procedure

Alphabetic List of Variables and Attributes						
#	Variable	Type	Len	Format	Informat	Label
9	CBORN	Num	8	CNTRY.	6.	Patient Country of Birth Code
8	HISP	Num	8	YN.	6.	Hispanic
15	MXDIAB	Num	8	YN.	6.	Diabetes
30	PLAT	Num	8	32.10	32.10	Labs: Platelets (x103/mm3)
5	SEX	Num	8	SEX.	6.	Sex
38	TBILI	Num	8	32.10	32.10	Labs: Total Bilirubin (mg/dL)
17	TOBACCO	Num	8	TOBAC.	6.	Tobacco Use
53	age_cat	Num	8	AGE_GROUP_NEW.		Age at Study Week (Years)
54	age_cat2	Num	8	AGE2FMT.		Age at Study Week (Years)
55	age_cat3	Num	8	AGE3FMT.		Age at Study Week (Years)
52	age_eri	Num	8			Age at Enrollment (Years)
39	alb_i	Num	8			Albumin (g/dL) imputed
16	alc_level	Num	8	ALC_LEVEL.		NIAAA Alcohol Risk Level in Past 12 Months
78	alc_risk12	Num	8	ALCFMT.		NIAAA Alcohol Risk Level in Past 12 Months
63	alt_cat	Num	8	ASTALTFT.		ALT x ULN
31	alt_i	Num	8			ALT (U/L), imputed
32	alt_norm	Num	8			ALT x ULN
65	apri	Num	8			APRI (AST-platelet ratio index)
66	apri_cat	Num	8	APRIFMT.		APRI
67	apri_cat2	Num	8	APRI2FMT.		APRI
76	asian	Num	8	ASIANFT.		Asian
62	ast_cat	Num	8	ASTALTFT.		AST x ULN
34	ast_i	Num	8			AST (U/L), imputed
35	ast_norm	Num	8			AST x ULN
20	bcp_mut	Num	8	BCPPC_MUT.		Any BCP Mutation (A1762T or G1764A) (Majority Call)
61	bdna_log_cat	Num	8	LGBDNAFT.		HBV DNA (log10 IU/mL)
12	bmi_a	Num	8			BMI (kg/m2)
77	bmi_raceadj	Num	8	BMIADJFT.		Race-adjusted BMI (kg/m2)
71	calc_pheno	Num	8	CALCPHENI.		Calculated Phenotype
2	case_id	Num	8			Masked ID

HBRN Adult Cohort Manuscript: Low Incidence of Adverse Outcomes in Adults with Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy

The CONTENTS Procedure

Alphabetic List of Variables and Attributes						
#	Variable	Type	Len	Format	Informat	Label
73	cirr_erl	Num	8	YESNO.		Baseline Cirrhosis (prior to though <24 weeks after enrollment)
3	cohortarg	Num	8	TARGENR_NEW.		Target or Non-targeted Record for Adult Cohort
10	continp	Num	8	CONTIN.		Continent of Birth
47	eQuant_i	Num	8			quant HBeAg (IU/mL) imputed
48	eQuant_log_i	Num	8			quant HBeAg (log10 IU/mL) imputed
46	eag_st	Num	8	PNE.		HBeAg Status
56	equant_cat	Num	8	QUANTFT.		quant HBeAg (IU/mL)
4	erldate	Num	8	MMDDYY8.	DATETIME22.3	Baseline Date of Evaluation
68	fib4	Num	8			FIB-4
69	fib4_cat	Num	8	FIB4FMT.		FIB-4
70	fib4_cat2	Num	8	FIB42FMT.		FIB-4
13	gen_cat	Num	8	GEN_CAT.		HBV Genotype (Central+Local) (one-time measure)
79	gen_comb	Num	8	GENCOMFT.		HBV Genotype
28	gt24fup	Num	8			>24 weeks of follow-up from enrollment (=1)
19	hbdur_bl	Num	8			Physician Estimated Duration of HBV (Years)
45	hbvdna	Num	8			HBV DNA (IU/mL) (Central+Local)
60	hbvdna_cat	Num	8	BDNAFMT.		HBV DNA (IU/mL)
43	hbvdna_i	Num	8			HBV DNA (IU/mL)
44	hbvdna_log_i	Num	8			HBV DNA (log10 IU/mL) imputed
24	hcv_dt	Num	8	MMDDYY8.	DATETIME22.3	Date HCV positive
25	hiv_dt	Num	8	MMDDYY8.	DATETIME22.3	Date HIV positive
22	ia_randdate	Num	8	MMDDYY8.		IA Trial Randomizatoin Date
42	inr	Num	8	32.10	32.10	Labs: INR
41	inr_i	Num	8			INR imputed
23	it_randdate	Num	8	MMDDYY8.		IT Trial Randomization Date
27	lstvisdt	Num	8	MMDDYY8.	DATETIME22.3	Last visit date (doedate)
1	orig_id	Char	9	\$9.	\$9.	ID at Enrollment Site
21	pc_mut	Num	8	BCPPC_MUT.		PC Mutation (G1896A) (Majority Call)
64	plat_cat	Num	8	PLATFMT.		Platelets (x103/mm3)
29	plat_i	Num	8			Platelets (x103/mm3) imputed

HBRN Adult Cohort Manuscript: Low Incidence of Adverse Outcomes in Adults with Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy

The CONTENTS Procedure

Alphabetic List of Variables and Attributes						
#	Variable	Type	Len	Format	Informat	Label
75	pregst_erl	Num	8	PREGSTFT.		Pregnancy Status at Enrollment
6	race_new	Num	8	RACE_NEW.		Race
7	race_oms	Char	60		\$60.	Race: Specify Other/Mixed
50	sQuant_i	Num	8			quant HBsAg (IU/mL) imputed
51	sQuant_log_i	Num	8			quant HBsAg (log10 IU/mL) imputed
49	sag_st	Num	8	PNE.		HBsAg Status
57	squant_cat	Num	8	QUANTFT.		quant HBsAg (IU/mL)
58	squant_log_cat	Num	8	LGQUANFT.		quant HBsAg (log10 IU/mL)
59	squant_log_cat4	Num	8	LGQUAN4F.		quant HBsAg (log10 IU/mL)
14	subgen	Num	8	SUBGEN.		CDC Subgenotype (Central) (one-time measure)
37	tbili_i	Num	8			Total Bilirubin (mg/dL) imputed
18	tranmode_com	Num	8	NEWTRANF.		Presumed Mode of Transmission
82	tx_durwks	Num	8			Duration on HBV Treatment if at/after Enrollment
85	tx_fl24	Num	8			Started HBV treatment <=24 weeks after enrollment (=1)
74	txstat_erl	Num	8	TXSTATFT.		HBV Treatment Status at Enrollment (does not account for Tx duration)
83	txstat_new	Num	8	TXSTRFT.		Started HBV Treatment at/after Enrollment (if duration of Tx <=24 weeks)
80	txstdt	Num	8	MMDDYY8.		Date Started HBV Treatment at/after Enrollment (if duration of Tx <=24 weeks)
81	txstopdt	Num	8	MMDDYY8.		Date Stopped HBV Treatment at/after Enrollment (if duration of Tx <=24 weeks)
11	waist_a	Num	8			Waist Circumference (cm)
72	wks_far	Num	8			Max weeks between ALT, AST, platelets for APRI and FIB-4
26	wksfup	Num	8			Weeks of follow-up
84	wkstotx	Num	8			Weeks after Enrollment to Starting HBV Treatment (if duration of Tx <=24 weeks)